Literature DB >> 15678124

Neuroprotection by osteopontin in stroke.

Robert Meller1, Susan L Stevens, Manabu Minami, Jennifer A Cameron, Sonya King, Holly Rosenzweig, Kristian Doyle, Nikola S Lessov, Roger P Simon, Mary P Stenzel-Poore.   

Abstract

Osteopontin (OPN) is a secreted extracellular phosphoprotein involved in diverse biologic functions, including inflammation, cell migration, and antiapoptotic processes. Here we investigate the neuroprotective potential of OPN to reduce cell death using both in vitro and in vivo models of ischemia. We show that incubation of cortical neuron cultures with OPN protects against cell death from oxygen and glucose deprivation. The effect of OPN depends on the Arg-Gly-Asp (RGD)-containing motif as the protective effect of OPN in vitro was blocked by an RGD-containing hexapeptide, which prevents integrin receptors binding to their ligands. Osteopontin treatment of cortical neuron cultures caused an increase in Akt and p42/p44 MAPK phosphorylation, which is consistent with OPN-inducing neuroprotection via the activation of these protein kinases. Indeed, the protective effect of OPN was reduced by inhibiting the activation of Akt and p42/p44 MAPK using LY294002 and U0126, respectively. The protective effect of OPN was also blocked by the protein synthesis inhibitor cycloheximide, suggesting that the neuroprotective effect of OPN required new protein synthesis. Finally, intracerebral ventricular administration of OPN caused a marked reduction in infarct size after transient middle cerebral artery occlusion in a murine stroke model. These data suggest that OPN is a potent neuroprotectant against ischemic injury.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15678124     DOI: 10.1038/sj.jcbfm.9600022

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  83 in total

1.  Osteopontin reduced hypoxia-ischemia neonatal brain injury by suppression of apoptosis in a rat pup model.

Authors:  Wanqiu Chen; Qingyi Ma; Hidenori Suzuki; Richard Hartman; Jiping Tang; John H Zhang
Journal:  Stroke       Date:  2011-01-27       Impact factor: 7.914

Review 2.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

3.  Recombinant osteopontin in cerebral vasospasm after subarachnoid hemorrhage.

Authors:  Hidenori Suzuki; Yu Hasegawa; Wanqiu Chen; Kenji Kanamaru; John H Zhang
Journal:  Ann Neurol       Date:  2010-11       Impact factor: 10.422

4.  Rapid degradation of Bim by the ubiquitin-proteasome pathway mediates short-term ischemic tolerance in cultured neurons.

Authors:  Robert Meller; Jennifer Anastasia Cameron; Daniel John Torrey; Corrin Erin Clayton; Andrea Nicole Ordonez; David Clifford Henshall; Manabu Minami; Clara Kay Schindler; Julie Anne Saugstad; Roger Pancoast Simon
Journal:  J Biol Chem       Date:  2006-01-23       Impact factor: 5.157

Review 5.  Cellular and molecular determinants of stroke-induced changes in subventricular zone cell migration.

Authors:  Christopher C Young; Keith J Brooks; Alastair M Buchan; Francis G Szele
Journal:  Antioxid Redox Signal       Date:  2010-11-01       Impact factor: 8.401

6.  Recombinant osteopontin attenuates brain injury after intracerebral hemorrhage in mice.

Authors:  Bihua Wu; Qingyi Ma; Hidenori Suzuki; Chunhua Chen; Wenwu Liu; Jiping Tang; John Zhang
Journal:  Neurocrit Care       Date:  2011-02       Impact factor: 3.210

7.  Progressive secondary neurodegeneration and microcalcification co-occur in osteopontin-deficient mice.

Authors:  Walter Maetzler; Daniela Berg; Claudia Funke; Freya Sandmann; Holger Stünitz; Corina Maetzler; Cordula Nitsch
Journal:  Am J Pathol       Date:  2010-06-03       Impact factor: 4.307

8.  Osteopontin Attenuates Secondary Neurodegeneration in the Thalamus after Experimental Stroke.

Authors:  Anne Ladwig; Rebecca Rogall; Jörg Hucklenbroich; Antje Willuweit; Michael Schoeneck; Karl-Josef Langen; Gereon R Fink; M Adele Rueger; Michael Schroeter
Journal:  J Neuroimmune Pharmacol       Date:  2018-11-28       Impact factor: 4.147

9.  Osteopontin is not critical for otoconia formation or balance function.

Authors:  Xing Zhao; Sherri M Jones; Wallace B Thoreson; Yunxia Wang Lundberg
Journal:  J Assoc Res Otolaryngol       Date:  2008-05-06

10.  Molecular mechanisms underlying hypothermia-induced neuroprotection.

Authors:  Yasushi Shintani; Yasuko Terao; Hiroyuki Ohta
Journal:  Stroke Res Treat       Date:  2010-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.